Ben Miles (@bennmiles) 's Twitter Profile
Ben Miles

@bennmiles

People, tech and biology. Ex. Product @StrateosLab, Transcriptic ⚗️. PhD Alum of @imperialcollege 🇬🇧

ID: 18717320

linkhttp://benmiles.xyz calendar_today07-01-2009 10:23:17

3,3K Tweet

745 Followers

795 Following

Formation Bio (@formationbio) 's Twitter Profile Photo

IMIDomics discovered the initial science, and now Formation Bio is taking it forward to clinical development. Today we announced our license of IMIDomics' first-in-class, Phase-1 ready anti-CD226 antibody targeting Ulcerative Colitis. Go behind the scenes with both teams here.

Zavain Dar (@zavaindar) 's Twitter Profile Photo

our most cutting edge companies are consistently Modal power users now, DIMENSION is also a proud Modal investor. thrilled to join Erik Bernhardsson & Akshat Bubna on their quest to reimagine infrastructure in the age of AI!!

Formation Bio (@formationbio) 's Twitter Profile Photo

New on the blog: how Formation Bio’s drug canvassing system uncovers “dark” or deprioritized assets, turning overlooked data into concrete signals for our BD team. Read the full piece here: formation.bio/blog/searching…

New on the blog: how Formation Bio’s drug canvassing system uncovers “dark” or deprioritized assets, turning overlooked data into concrete signals for our BD team.

Read the full piece here: formation.bio/blog/searching…
Formation Bio (@formationbio) 's Twitter Profile Photo

Today we're announcing a new addition to our pipeline: LNK01006, a next-generation CNS-penetrant TYK2 inhibitor licensed from Lynk Pharmaceuticals. Phase 1 is planned for the first half of 2026. In our latest video, hear from our team who brought the LNK01006 deal to life, including more

Formation Bio (@formationbio) 's Twitter Profile Photo

New on our blog: Cohen Karnell, software engineer at Formation Bio, shares how we transformed a decade’s worth of unstructured clinical trial data into a standardized data foundation for faster, smarter clinical development. Read here: formation.bio/blog/structuri…

New on our blog: Cohen Karnell, software engineer at Formation Bio, shares how we transformed a decade’s worth of unstructured clinical trial data into a standardized data foundation for faster, smarter clinical development. Read here: formation.bio/blog/structuri…
Formation Bio (@formationbio) 's Twitter Profile Photo

Proud to announce that Formation Bio has acquired worldwide rights, excluding greater China, to FHND5032, a small-molecule miR-124 activator for autoimmune diseases. This marks our third acquisition in six months, and we plan to enter the clinic in 2026. Go behind the scenes of